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BACKGROUND
In patients with traumatic brain injury, hypothermia can reduce intracranial hyper-
tension. The benefit of hypothermia on functional outcome is unclear.
METHODS
We randomly assigned adults with an intracranial pressure of more than 20 mm Hg 
despite stage 1 treatments (including mechanical ventilation and sedation manage-
ment) to standard care (control group) or hypothermia (32 to 35°C) plus standard 
care. In the control group, stage 2 treatments (e.g., osmotherapy) were added as 
needed to control intracranial pressure. In the hypothermia group, stage 2 treatments 
were added only if hypothermia failed to control intracranial pressure. In both 
groups, stage 3 treatments (barbiturates and decompressive craniectomy) were 
used if all stage 2 treatments failed to control intracranial pressure. The primary 
outcome was the score on the Extended Glasgow Outcome Scale (GOS-E; range, 
1 to 8, with lower scores indicating a worse functional outcome) at 6 months. The 
treatment effect was estimated with ordinal logistic regression adjusted for pre-
specified prognostic factors and expressed as a common odds ratio (with an odds 
ratio <1.0 favoring hypothermia).
RESULTS
We enrolled 387 patients at 47 centers in 18 countries from November 2009 
through October 2014, at which time recruitment was suspended owing to safety 
concerns. Stage 3 treatments were required to control intracranial pressure in 54% 
of the patients in the control group and in 44% of the patients in the hypothermia 
group. The adjusted common odds ratio for the GOS-E score was 1.53 (95% confi-
dence interval, 1.02 to 2.30; P = 0.04), indicating a worse outcome in the hypother-
mia group than in the control group. A favorable outcome (GOS-E score of 5 to 8, 
indicating moderate disability or good recovery) occurred in 26% of the patients in 
the hypothermia group and in 37% of the patients in the control group (P = 0.03).
CONCLUSIONS
In patients with an intracranial pressure of more than 20 mm Hg after traumatic 
brain injury, therapeutic hypothermia plus standard care to reduce intracranial 
pressure did not result in outcomes better than those with standard care alone. 
(Funded by the National Institute for Health Research Health Technology Assess-
ment program; Current Controlled Trials number, ISRCTN34555414.)
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In Europe, traumatic brain injury is the most common cause of permanent dis-ability in people younger than 40 years of 
age, with the annual cost exceeding €33 billion 
(approximately $37.5 billion in U.S. dollars).1,2 
Recent statistics show a 21% increase in the in-
cidence of traumatic brain injury during the past 
5 years — three times greater than the increase 
in population. Despite this, management of 
traumatic brain injury has been underrepresented 
in medical research as compared with other 
health problems.3 Consequently, there are few 
data to support the commonly used stage 2 inter-
ventions (Fig. 1) for the management of trau-
matic brain injury,4-6 with even the use of intra-
cranial-pressure monitoring being debated.7
Hypothermia is one treatment option for this 
patient group.8-12 Some previous trials of early 
induction of prophylactic hypothermia have 
shown benefit, but the trials of hypothermia for 
neuroprotection that were judged to be higher in 
quality and to have a lower risk of bias (on the 
basis of assessment of randomization procedures, 
blinding, outcome assessment, and completeness 
of the data)11 have shown trends toward unfavor-
able outcomes13,14 or were stopped for futility.15,16 
Although hypothermia is routinely used to treat 
elevated intracranial pressure in patients with 
traumatic brain injury in some intensive care 
units (ICUs), its effect on outcome in this con-
text has limited evaluation.17 We conducted a 
trial of therapeutic hypothermia for elevated in-
tracranial pressure in which we tested hypother-
mia in the way that many clinicians currently 
use it.18-21
Me thods
Trial Design and Oversight
The European Study of Therapeutic Hypothermia 
(32–35°C) for Intracranial Pressure Reduction 
after Traumatic Brain Injury (the Eurotherm3235 
Trial) aimed to recruit 600 patients who had a 
traumatic brain injury. The first patient was 
enrolled in November 2009, and the trial was 
stopped early in October 2014 for participant 
safety.
The trial protocol was developed by the first, 
second, fourth, and last authors in consultation 
with an international advisory board. The trial 
was conducted and reported with fidelity to the 
study protocol. Full details of the trial protocol 
have been published previously,22 and the proto-
col is available with the full text of this article at 
NEJM.org. After the pilot phase of the trial, the 
inclusion criteria and power calculation were 
refined as described below. The authors vouch 
for the accuracy and completeness of the data 
and analyses. Data were gathered by investiga-
tors at the trial sites (see the Supplementary 
Appendix, available at NEJM.org).
Ethical approval was obtained from the Scot-
land A Research Ethics Committee, the Bradford 
Research Ethics Committee, and ethics commit-
tees in another 14 countries. Owing to the inca-
pacitated state of the potential participants, it 
was not possible to obtain consent directly from 
them. Written informed consent was therefore 
sought from each eligible patient’s nearest rela-
tive or person designated to give consent. Early 
consent was obtained when possible to prevent a 
delay between a rise in intracranial pressure and 
potential randomization.
An independent steering committee and inde-
pendent data and safety monitoring committee 
reviewed the trial regularly, assessing conduct, 
progress, and safety (see the Supplementary Ap-
pendix). Trial recruitment was stopped on the 
advice of the data and safety monitoring com-
mittee after its ninth meeting (Table S11 in the 
Supplementary Appendix).
Participants
All patients admitted to the ICU after a trau-
matic brain injury who had intracranial-pressure 
monitoring in place were screened. Eligible pa-
tients were believed to be of legal age for con-
sent. Other inclusion criteria were a primary, 
closed traumatic brain injury; an intracranial 
pressure of more than 20 mm Hg for at least 
5 minutes after stage 1 treatments (Fig. 1), with 
no obvious reversible cause; an initial head in-
jury that had occurred no more than 10 days 
earlier; the availability of a cooling device or 
technique for more than 48 hours; a core tem-
perature of at least 36°C (at the time of random-
ization); and an abnormal computed tomo-
graphic scan of the brain. Patients who were 
already receiving therapeutic hypothermia or who 
were unlikely to survive for the next 24 hours 
were excluded. Other exclusion criteria were the 
administration of barbiturate infusion before 
randomization, a temperature of 34°C or less at 
hospital admission, and pregnancy.
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The inclusion criteria were changed in Janu-
ary 2012, on the basis of the pilot-phase find-
ings,23 to remove an upper age limit (previously 
65 years) and to increase the time from injury 
from 72 hours to 10 days. These changes allowed 
the enrollment of older patients and those with 
evolving brain swelling.
ICUs in hospitals that provide specialist neu-
rologic treatment for traumatic brain injury were 
recruited (25 centers in the United Kingdom and 
39 elsewhere). Evidence of expertise with intra-
cranial-pressure monitoring and therapeutic 
cooling were necessary.
Data Collection
An online case-report form (Lincoln, Paris) was 
used for collection of data (Fig. S8 in the Supple-
mentary Appendix), including baseline demo-
Figure 1. Stages of Therapeutic Management and Trial Follow-up.
CSF denotes cerebrospinal fluid, EEG electroencephalographic, GOS-E Extended Glasgow Outcome Scale, ICU inten-
sive care unit, and MOHS modified Oxford Handicap Scale.
Intracranial pressure >20 mm Hg within 10 days after injury
Stage 3 Options (if required)
Day 28, Hospital Discharge, or Death
MOHS grade, length of stay in ICU and hospital
6-Mo Follow-up
GOS-E score
Stage 1
Stage 2
Stage 3
Trial Follow-up
Traumatic Brain Injury
Stage 1 treatment:
Admission to ICU
Mechanical ventilation
Sedation
Analgesia with or without paralysis
Head of bed elevated to 30 degrees 
Intravenous fluids with or without inotropes to maintain
mean arterial pressure ≥80 mm Hg
Stage 1 options:
Ventriculostomy with or without CSF drainage
Surgical removal of space-occupying lesions
Control Group
Continue stage 1 treatments and add stage 2 
treatments without therapeutic hypothermia
Stage 2 treatment:
Mannitol (maintain serum osmolarity
<315 mOsm per kilogram of water)
Hypertonic saline (avoid in hyponatremia,
caution with cardiac or pulmonary problems)
Inotropes to maintain cerebral perfusion
pressure ≥60 mm Hg
Barbiturates not permitted
Hypothermia Group
Continue stage 1 treatments and initiate
hypothermia
Add stage 2 treatments only if needed
Barbiturates not permitted
Continued medical care
Barbiturate therapy with processed EEG monitoring
Decompressive craniectomy
Further surgical intervention if required
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graphic information and data on completion of 
stage 1 interventions; intracranial pressure and 
temperature at randomization; intracranial pres-
sure, mean arterial pressure, cerebral perfusion 
pressure, and temperature measured hourly on 
days 1 through 7; failure of stage 2 therapy to 
control intracranial pressure; new pneumonia; 
and functional outcome. This trial was pragmat-
ic, with a focus on patient-oriented outcomes; 
therefore, we did not collect data on which stage 2 
therapies were delivered to patients.5
Randomization and Study Treatment
Participants were randomly assigned to standard 
care (control group) or therapeutic hypothermia 
plus standard care (intervention group). Random-
ization was performed with the use of a minimi-
zation procedure to balance assignments accord-
ing to center, age, Glasgow Coma Scale (GCS) 
motor score, time from injury, and pupillary re-
sponse. The online case-report form ensured 
minimization (with a random element) and 
concealment of allocation to study groups. The 
trial had an open-label design, with patients, 
families, and treating clinicians aware of the 
study-group assignments. Scoring of the primary 
outcome measure (described below) was blinded.
According to the study protocol, hypothermia 
was induced by a bolus of intravenous, refriger-
ated 0.9% sodium chloride (20 to 30 ml per kilo-
gram of body weight) and thereafter maintained 
with the usual cooling technique of each site. 
Guidelines were provided for induction and 
maintenance of hypothermia, rewarming, and 
detection and treatment of shivering in the in-
tervention group (Fig. S1, S2, and S3 in the 
Supplementary Appendix).
Core temperature in the hypothermia group 
was reduced by the minimum required to main-
tain an intracranial pressure of 20 mm Hg or 
less (in keeping with guidelines of the Brain 
Trauma Foundation24), within the limits of 32 to 
35°C. Stage 2 treatments were added if hypo-
thermia failed to control intracranial pressure. 
Stage 3 treatments were used for patients whose 
intracranial pressure was not controlled by hypo-
thermia and all other stage 2 treatments.
Hypothermia was maintained for at least 48 
hours in the intervention group and continued 
for as long as necessary to control intracranial 
pressure. Rewarming was considered after 48 
hours at a rate of 0.25°C per hour, provided that 
intracranial pressure was 20 mm Hg or less. The 
control group also received stage 2 and 3 treat-
ments but without hypothermia (Fig. 1).
Outcomes
The primary outcome measure was the score on 
the Extended Glasgow Outcome Scale (GOS-E) at 
6 months after injury.25,26 The eight-point scale 
assesses the effects of traumatic brain injury on 
function in major areas of life. A GOS-E score of 
1 indicates death, 2 indicates a vegetative state, 
3 or 4 indicates severe disability, 5 or 6 indicates 
moderate disability, and 7 or 8 indicates good re-
covery (Table S2 in the Supplementary Appendix). 
The GOS-E questionnaire (Fig. S4 in the Supple-
mentary Appendix) was sent by mail to surviving 
participants from the trial office in Edinburgh. 
When this was not possible, a local staff mem-
ber contacted the patient by telephone to com-
plete the questionnaire. An investigator who was 
unaware of the study-group assignments scored 
all outcomes according to the standardized ap-
proach (Fig. S4 in the Supplementary Appendix). 
The manually calculated scores were automati-
cally checked in the trial database with the use 
of a specially developed algorithm. An indepen-
dent expert was consulted in the few cases in 
which adjudication was needed.
Secondary outcomes were 6-month mortality, 
lack of intracranial-pressure control (failure of 
all stage 2 therapies to control intracranial pres-
sure to ≤20 mm Hg), incidence of pneumonia 
during days 1 through 7 after randomization, 
length of ICU stay, and grade on the modified 
Oxford Handicap Scale (MOHS; a score of 0 indi-
cates no symptoms, 1 minor symptoms, 2 some 
restriction, 3 dependent, 4 fully dependent, and 
5 death) (Table S3 in the Supplementary Appen-
dix)27 at 28 days or discharge from an acute-care 
hospital (whichever came first).
Data were collected on serious adverse events, 
including bleeding, cardiovascular instability, 
thermal burns, and a cerebral perfusion pressure 
of less than 50 mm Hg. Data on other adverse 
events were not collected, because many un-
toward events are expected in patients with trau-
matic brain injury who are admitted to the ICU.
Statistical Analysis
As a result of the internal pilot phase, the sam-
ple size for the full trial was reduced from 1800 to 
600 patients.23 Two factors contributed to this 
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decision: our original sample size may have un-
derestimated the possible benefit of hypothermia 
because, unlike participants in most previous 
trials, participants in the Eurotherm3235 Trial 
had evidence of brain swelling (raised intracra-
nial pressure); and we showed that an enhanced 
cooling intervention could be delivered, as de-
scribed by Peterson et al.28 These data therefore 
informed the revised power calculation.
Using an ordinal analysis of the GOS-E scores 
together with covariate adjustment (primary ef-
ficacy analysis), we were able to increase the 
statistical efficiency of the analysis,29,30 so that a 
trial involving 600 patients would have power 
equivalent to that of a trial involving 1000 pa-
tients that assessed a binary outcome. We calcu-
lated that with such an analysis, the study would 
have the equivalent of 80% power to detect a rate 
of unfavorable outcome (GOS-E score of 1 to 4) 
that was 9 percentage points lower with hypo-
thermia than with standard care (51% vs. 60%), 
at the 5% significance level (two-sided).
All analyses were performed with SAS soft-
ware, version 9.3 (SAS Institute). Analyses were 
performed on an intention-to-treat basis, incor-
porating all patients who underwent randomiza-
tion and for whom outcome data were available, 
with patients evaluated according to their as-
signed intervention.
For the primary analysis, the distribution of 
the 6-month GOS-E scores between the two 
groups (hypothermia vs. control) was compared 
with the use of ordinal logistic regression30 and 
with adjustment for the following baseline co-
variates: age (included as a continuous variable, 
with the use of a linear term in the regression 
model), postresuscitation GCS motor score (1 or 2 
[no or extensor response] vs. 3 to 6 [flexion or 
better response]) (Table S1 in the Supplementary 
Appendix), time from injury (<12 hours vs. ≥12 
hours), and pupillary response (both reacting vs. 
one reacting vs. neither reacting; included as an 
unordered categorical variable in the regression 
model).
For this analysis, we collapsed the eight-point 
GOS-E to six categories by pooling death with a 
vegetative state and lower severe disability. This 
ensured that the analysis would not favor an 
intervention that reduced mortality at the ex-
pense of increasing the proportion of severely 
disabled survivors.
Prespecified subgroups for the primary analy-
sis were defined on the basis of the baseline co-
variates described above, the location of the 
center (United Kingdom vs. elsewhere), and the 
volume of the center (≥10 vs. <10 patients). We 
performed these analyses by including an inter-
action term between intervention and the rele-
vant covariate in the ordinal logistic-regression 
model; a stricter level of statistical significance 
(P<0.01) was used owing to their exploratory 
nature.
MOHS grades were analyzed in the same way 
as GOS-E scores, but we collapsed the six grades 
to four categories by grouping dependent, fully 
dependent, and death (Table S9B in the Supple-
mentary Appendix). In the analysis of the between-
group difference in mortality, Cox proportional-
hazards regression was used to estimate the 
intervention effect.
Other continuous outcomes were tested with 
an analysis of covariance; for binary outcomes, 
logistic regression was used. Intracranial pres-
sure, core temperature, mean arterial pressure, 
and cerebral perfusion pressure on days 1 through 
7 were analyzed post hoc with the use of a linear 
model, with study days as repeated measure-
ments with a compound-symmetry covariance 
matrix. All these analyses used the same covari-
ates as were prespecified for GOS-E scores to-
gether with the baseline value of the relevant 
variable.
R esult s
Recruitment
A total of 2498 patients at 55 centers in 18 coun-
tries were assessed for trial eligibility, and 387 
patients at 47 centers in 18 countries underwent 
randomization, of whom 205 (53.0%) were re-
cruited in the United Kingdom (Table S4 in the 
Supplementary Appendix). Patients underwent 
randomization between November 2009 (pilot 
phase to September 15, 2011) and October 2014, 
at which time recruitment was stopped (Fig. S6 
in the Supplementary Appendix). The most com-
mon reasons for exclusion from the trial were an 
intracranial pressure of 20 mm Hg or less (41% 
of 2111 exclusions), the unlikelihood of survival 
(8%), and current receipt of therapeutic hypo-
thermia (6%). Recruitment was stopped after the 
steering committee concluded that there were 
signs of harm with the treatment being evalu-
ated and that a result of futility, at best, would 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on November 13, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 6
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
be expected if the trial were to continue. These 
findings became apparent when the committee 
examined the designated primary outcome mea-
sure analyzed according to the prespecified sta-
tistical analysis plan (Table S11 in the Supple-
mentary Appendix).
On an intention-to-treat basis, 195 partici-
pants were randomly assigned to the hypother-
mia group and 192 to the control group. Of the 
387 randomly assigned patients, 386 received 
the intended treatment (1 patient in the hypo-
thermia group was withdrawn before receiving 
the intervention), and 376 (188 in each group) 
were evaluated for the primary outcome (Fig. S6 
in the Supplementary Appendix). Baseline char-
acteristics of the two groups were similar in all 
respects (Table 1, and Table S5 in the Supple-
mentary Appendix). There were no significant 
differences between groups with respect to pre-
randomization neurosurgery for single or mul-
tiple procedures (Table S6 in the Supplementary 
Appendix).
Intracranial Pressure and Core Temperature
Mean daily intracranial pressure was similar in 
the two groups (Fig. 2 and Table 2). Core tem-
perature was substantially lower in the hypo-
thermia group than in the control group during 
the first 4 days after randomization. During that 
time period, there were fewer first occurrences 
of failure of stage 2 therapy to control intra-
cranial pressure in the hypothermia group 
than in the control group (57 vs. 84) (Table S7 
in the Supplementary Appendix). This resulted 
in more frequent use of stage 3 treatments on 
days 1 through 7 in the control group than in 
the hypothermia group (102 of 189 patients 
[54.0%] vs. 84 of 192 patients [43.8%]). Barbitu-
rate-infusion therapy was used more often in the 
control group than in the hypothermia group 
(41 patients vs. 20 patients) during days 1 through 
4 after randomization, but decompressive crani-
ectomy was not used more often (27 patients in 
each group) (Table S8 in the Supplementary Ap-
pendix).
A repeated-measures analysis was performed 
to compare the difference between the groups 
with respect to the change from day 1 to day 7 
after randomization in core temperature, intra-
cranial pressure, mean arterial pressure, and cere-
bral perfusion pressure. There was a significant 
difference with respect to core temperature only 
(Table 2 and Fig. 2).
Primary Outcome
Six months after injury, the distribution of GOS-E 
scores was shifted in an unfavorable direction in 
the hypothermia group (adjusted common odds 
ratio, 1.53; 95% confidence interval [CI], 1.02 to 
2.30; P = 0.04) (Table 2, and Table S9A in the 
Supplementary Appendix). Favorable outcomes 
(GOS-E score of 5 to 8, indicating moderate dis-
ability or good recovery) occurred in 49 of 191 
patients (25.7%) in the hypothermia group and 
in 69 of 189 patients (36.5%) in the control 
group (P = 0.03). The results without adjustment 
for prespecified covariates were similar for the 
GOS-E score (unadjusted common odds ratio, 
1.55; 95% CI, 1.05 to 2.29; P = 0.03). The risk of 
death (hazard ratio, 1.45; 95% CI, 1.01 to 2.10; 
P = 0.047) favored the control group (Table 2, 
and Table S9A and Fig. S7 in the Supplementary 
Appendix).
Subgroup analysis showed no significant in-
teraction effect between the intervention and pre-
specified subgroups (Fig. S5 in the Supplemen-
tary Appendix). The rate of adherence, defined 
as more than 80% of core temperature measure-
ments within range for days 1 through 4, was 
64.8% in the hypothermia group (32 to 35°C) 
and 68.8% in the control group (≥36°C). Serious 
adverse events were reported more often in the 
hypothermia group than in the control group 
(33 events vs. 10 events) (Table S10 in the Sup-
plementary Appendix).
Discussion
In this trial involving patients with traumatic 
brain injury and an intracranial pressure of 
more than 20 mm Hg for at least 5 minutes 
despite stage 1 therapy, hypothermia plus stan-
dard care did not result in outcomes better than 
those with standard care alone. The trial was 
stopped early owing to safety concerns, which 
introduces the risk of bias, but the results sug-
gest that outcomes were worse with hypother-
mia than with standard care alone.
The Eurotherm3235 Trial was a large ran-
domized, controlled trial that tested therapeutic 
hypothermia as the primary (stage 2) interven-
tion to reduce intracranial pressure after brain 
trauma. Literature at the time of protocol devel-
opment showed that at least one episode of in-
tracranial pressure of more than 20 mm Hg oc-
curred in 50% of patients with traumatic brain 
injury who received mechanical ventilation and 
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intercranial-pressure monitoring.31 In contrast, 
data collected during the screening of patients 
for this trial indicated that fewer patients than 
expected had a rise in intracranial pressure.
Standard care followed best practice (Brain 
Trauma Foundation guidelines) but was not pre-
scribed in the protocol. There were guidelines 
for hypothermia maintenance and control of 
shivering, but only induction of hypothermia, 
rather than a specific maintenance technique, 
was prescribed in the protocol. Centers used 
whichever cooling technique they would normally 
Characteristic
Hypothermia 
(N = 195)
Control 
(N = 192)
Age <45 yr — no. (%) 131 (67.2) 131 (68.2)
Age — yr 37.4±15.4 36.7±14.9
GCS motor score — no. (%)†
1 or 2 56 (28.7) 51 (26.6)
3–6 139 (71.3) 141 (73.4)
Pupillary response — no. (%)
Both reacting 144 (73.8) 143 (74.5)
One or neither reacting 51 (26.2) 49 (25.5)
Time from injury — no. (%)
<12 hr 19 (9.7) 15 (7.8)
≥12 hr 176 (90.3) 177 (92.2)
Intracranial pressure at randomization — mm Hg 25.2±4.8 25.5±6.4
Core temperature at randomization — °C 37.0±0.72 37.1±0.72
Isolated TBI — no. (%) 123 (63.1) 133 (69.3)
Marshall classification — no. (%)‡
Diffuse axonal injury I–III 72 (36.9) 78 (40.6)
Diffuse axonal injury IV 21 (10.8) 15 (7.8)
Any lesion surgically removed 46 (23.6) 52 (27.1)
High-density or mixed-density lesion 56 (28.7) 47 (24.5)
Mechanism of injury — no. (%)§
Road-traffic accident, pedestrian 22 (11.3) 31 (16.1)
Road-traffic accident, motor vehicle 68 (35.1) 51 (26.6)
Bicycling accident 7 (3.6) 10 (5.2)
Fall 78 (40.2) 78 (40.6)
Sports injury 1 (0.5) 1 (0.5)
Assault 18 (9.3) 21 (10.9)
*  Plus–minus values are means ±SD. There were no significant differences between groups for these baseline measures. 
Other baseline characteristics are presented in Tables S5 and S6 in the Supplementary Appendix. TBI denotes traumatic 
brain injury.
†  The Glasgow Coma Scale (GCS) motor score was measured on hospital admission. A score of 1 indicates that the patient 
makes no movements, a score of 2 indicates extension to painful stimuli, a score of 3 indicates abnormal flexion, a score 
of 4 indicates normal flexion, a score of 5 indicates that the patient localizes painful stimuli, and a score of 6 indicates 
that the patient obeys commands.
‡  The Marshall classification of traumatic brain injury is based on a review of computed tomographic scans, which were ob-
tained at the screening visit. A diffuse injury indicates that no high-density or mixed-density lesions of more than 25 mm3 
are present. Diffuse injury I indicates no visible intracranial pathologic features, diffuse injury II indicates that cisterns 
are present with a midline shift of 0 to 5 mm or that lesion densities are present, diffuse injury III indicates that cisterns 
are compressed or absent with a midline shift of 0 to 5 mm, and diffuse injury IV indicates a midline shift of more than 
5 mm.
§  Data were missing for one patient in the hypothermia group.
Table 1. Baseline Characteristics of the Study Patients.*
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on November 13, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 8
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
use. Therefore, the results are not due to any one 
cooling method or to any treatment prescribed 
as part of the trial protocol. We believe this en-
hances the validity and generalizability of the 
trial and its results, because the intervention 
studied is already used in clinical practice and 
was tested in the way that centers currently use it.
In this trial, barbiturate infusion was re-
served for patients who had uncontrolled intra-
cranial pressure despite all stage 1 and stage 2 
treatments; barbiturate infusion to reduce intra-
cranial pressure32 was used more frequently and 
earlier in the control group than in the hypo-
thermia group (Table S8 in the Supplementary 
Appendix). It is plausible that barbiturate infu-
sion may have been beneficial, but that hypoth-
esis requires further testing. There was no dif-
ference in the use of decompressive craniectomy33 
between the two groups.
We found no significant between-group dif-
ference according to the time from injury to 
initiation of hypothermia (<12 or ≥12 hours), a 
finding that is contrary to that of a previous 
review.34 However, there were too few patients 
who underwent randomization less than 12 hours 
after injury to be confident of having excluded a 
subgroup effect for the time from injury. The 
trials of hypothermia for neuroprotection that 
were judged to be of higher quality and to have 
a lower risk of bias11 have shown trends toward 
unfavorable outcomes13,14 or were stopped for 
futility.15,16
The trial sponsor and steering committee ac-
cepted the recommendation of the data and safe-
ty monitoring committee in full and terminated 
recruitment early. Early stopping of any trial can 
potentially reduce the external validity of the 
results; however, the burden of proof required 
for early stopping for possible harm is consider-
ably lower than that for overwhelming evidence 
of efficacy.35 In this case, the remaining GOS-E 
scores collected after the “stopping” decision 
Figure 2. Physiological Measurements.
Shown are estimated means and 95% confidence intervals (I bars), calculated with the use of a repeated-measures 
linear analysis.
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confirmed the result and did not show regres-
sion to the mean and a resultant lack of evidence 
(Table S11 in the Supplementary Appendix).
A limitation of the study is the lack of blind-
ing to the intervention, which is problematic in 
all trials of therapeutic hypothermia. However, 
because cooling to normothermia was permitted 
in the standard-care group, it is possible that 
there was masking of the intervention to patients 
and relatives in some cases. Outcome scoring 
was blinded. Lack of blinding was why, in our 
opinion, more serious adverse events were re-
ported in the hypothermia group. In the control 
group, the same clinical events may have been 
considered expected and may not have been re-
ported as serious adverse events.
The trial was designed to be pragmatic, fo-
cused on functional outcome rather than on de-
tailed mechanistic pathways. The intensity of a 
stage 2 therapy is adjusted according to the effect 
on intracranial pressure, mean arterial pressure, 
and cerebral perfusion pressure. There were no 
clinically important differences in these variables 
between the two groups. Given that there were 
no or limited data on the benefits and harms of 
standard stage 2 interventions, we elected not to 
record which stage 2 therapies were delivered to 
patients. The findings suggesting possible harm 
of hypothermia could be due to a biologic effect 
of hypothermia or due to the harms or benefits 
of the other therapies used differentially in the 
two groups. This trial did not assess the benefits 
and risks of hypothermia used in patients with 
traumatic brain injury who have severe intracra-
nial hypertension that is refractory to all stage 2 
treatments before initiation of hypothermia.
The benefits and harms of other interven-
tions that successfully reduce intracranial pres-
sure have not been assessed. More adequately 
powered clinical trials of hypertonic therapy, 
barbiturates, and hyperventilation are required.5
In patients with traumatic brain injury, thera-
peutic hypothermia plus standard care success-
fully reduced intracranial pressure. This inter-
vention, however, did not improve functional 
recovery as compared with standard care alone.
Variable Estimate (95% CI) P Value
Physiological measurements†
Adjusted mean difference in ICP on days 1–7 — mm Hg −0.48 (−2.04 to 1.08) 0.55
Adjusted mean difference in core temperature on days 1–7 — °C −2.14 (−2.34 to −1.94) <0.001
Adjusted mean difference in mean arterial pressure on days 1–7 — mm Hg 1.20 (−0.46 to 2.86) 0.16
Adjusted mean difference in cerebral perfusion pressure on days 1–7 — mm Hg 1.61 (−0.36 to 3.58) 0.11
Primary analysis: adjusted common odds ratio for GOS-E score at 6 mo‡§ 1.53 (1.02 to 2.30)¶ 0.04
Adjusted odds ratio for unfavorable outcome‡‖ 1.69 (1.06 to 2.70)¶ 0.03
Unadjusted hazard ratio for death at 6 mo 1.45 (1.01 to 2.10)  0.047
Adjusted mean difference in squared proportion of ICP measurements of ≤20 mm Hg on days 1–7‡   440 (−160 to 1000) 0.47
Adjusted odds ratio for presence of pneumonia on days 3–7‡ 1.04 (0.69 to 1.58)¶ 0.84
Adjusted mean difference in log-transformed length of ICU stay — log hours‡ 0.05 (0.11 to 0.22) 0.54
Adjusted common odds ratio for MOHS grade at 28 days‡** 1.65 (0.91 to 3.02)¶ 0.10
*  CI denotes confidence interval, ICP intracranial pressure, and ICU intensive care unit.
†  Values were calculated with the use of a repeated-measures model adjusted for age, postresuscitation GCS motor score, time from injury, 
pupillary response, study day, and (when available) baseline value. These are post hoc analyses.
‡  Results were adjusted for age, postresuscitation GCS motor score, time from injury, and pupillary response.
§  The eight-point Extended Glasgow Outcome Scale (GOS-E) was collapsed to six categories by pooling death (score of 1) with vegetative 
state (score of 2) and lower severe disability (score of 3) (Table S9A in the Supplementary Appendix).
¶  An odds ratio or common odds ratio of less than 1 corresponds to a benefit for hypothermia over control.
‖  The eight-point GOS-E was collapsed to two categories: favorable outcome (score of 5 to 8) and unfavorable outcome (score of 1 to 4) 
(Table S9A in the Supplementary Appendix).
**  The six grades of the modified Oxford Handicap Scale (MOHS) were collapsed to four categories by pooling dependent, fully dependent, 
and death (Table S9B in the Supplementary Appendix).
Table 2. Analysis of Primary and Secondary Outcomes for Hypothermia versus Control.*
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